How to increase female libido after menopause


How to increase female libido after menopause

Low Libido in Postmenopausal Women

Objectives: The purpose of this article is to educate nurse practitioners about low libido in postmenopausal women. After reading this article, the nurse practitioner should be able to describe the female sexual response identify and describe the biological and motivational causes of low libido in postmenopausal women, identify methods of diagnosing low libido in women, and describe methods of treating low libido in women.

There was a time when a diminished sex drive or inadequate sexual performance was a topic for late-night comedy routines or water-cooler gossip. Viagra and its counterparts changed that. A new sexual revolution has emerged, and this time it features baby boomers. Now, in addition to treating the expected cardiac and orthopedic anomalies in middle age and beyond, primary care providers are caught up in the medicalization of sexual satisfaction. Researchers estimate that at least 50% of adult women experience sexual dissatisfaction in the form of decreased desire and arousal.

Classifying Low Libido

Female sexual dysfunction (FSD) is a clinical condition defined as “persistent or recurring reduction of sex drive or aversion to sexual activity, difficulty becoming aroused, inability to reach orgasm, or pain during sexual intercourse.”3 According to this definition, FSD encompasses everything from anorgasmia to dyspareunia. This article focuses on postmenopausal women and uses the terms “low libido” and “reduced sex drive” interchangeably.

The International Consensus Development Conference on Female Sexual Dysfunction developed a classification system that includes the components of FSD used by the Food and Drug Administration (FDA) when evaluating the efficacy of drugs (Table 1).4 The same classification list is in the Diagnostic and Statistic Manual of Mental Disorders.5 Using these criteria, low libido would be clinically diagnosed as hypoactive sexual desire disorder (HSDD) or female sexual arousal disorder (FSAD).

The Female Sexual Response

To understand available treatments and related research efforts, knowledge of the female sexual response is necessary. During sexual activity, the brain becomes stimulated through somatic pathways that arise from the skin and travel through the dorsal nerve of the clitoris to the pudendal nerve. The stimulated brain then increases neurologic output to clitoral receptors. This in turn leads to the conversion of L-arginine (stored in clitoral tissue) into nitric oxide. The presence of nitric oxide results in vasodilation of the clitoral erectile tissue, smooth relaxation of the arteriole, and subsequent clitoral-vaginal engorgement. At the same time, similar neurogenic impulses are sent to the vagina, leading to increased lubrication, vaginal wall engorgement and increased vaginal diameter.

Hormones play an integral role in the female sexual response as well. Adequate estrogen and testosterone must be available for the brain to sense incoming arousal stimuli.Research indicates that estrogen preserves the vascular function of female sex organs and affects genital sensation.7 Estrogen receptors are located in the reproductive organs as well as the urethra and bladder neck. The hormone is believed to promote blood flow to these areas and to assist with lubrication and thickening of the vaginal epithelium, characteristics that make intercourse more comfortable.8 In addition, estrogen influences the central nervous system during sexual excitement by mediating the expression of vaginal and clitoral nitric oxide synthase.

Much less has been determined about the impact of testosterone on female sexual function, but many studies have linked a decrease in testosterone to diminished libido. Testosterone’s specific role in female sexual response is unclear. Some researchers have hypothesized that it is the hormone of sexual desire in women and claim that it has an additional effect on general well-being.8 Pharmaceutical companies are paying particular attention to testosterone, with the hope that a synthetic androgen will provide the same sexual boost for women that it has for men.

Causes of Low Libido

There are multiple and complex reasons why postmenopausal women might be less inclined to engage in or enjoy sexual activity. These can be viewed in the framework of biological, motivational-affective and cognitive domains.6 Assessing patients in this manner allows you to more clearly identify the cause of libido changes, as well as the direction and goal of treatment.

Biological Causes

Whether menopause occurs naturally or surgically, its associated physiologic changes have a significant impact. Age and the presence or lack of intact ovaries distinguishes these patients and helps determine treatment goals.

Biological changes can be divided into physical and hormonal alterations. Physical changes after menopause are most significant in women who have reached menopause naturally. About half of these women report some degree of urogenital atrophy, vaginal dryness and dyspareunia.2 Changes in the levator ani muscle and perineal membrane may also lead to painful intercourse or anorgasmia.11 These changes are believed to be the result of aging as well as decreased estrogen production. Younger postmenopausal women typically report fewer symptoms.

Hormonal changes play a significant role in postmenopausal women as well. A decrease in estrogens – and, more importantly, androgens – can deprive a woman of the ingredients needed to maintain a healthy sex drive. These hormones appear to act on the central and peripheral nervous systems to enhance reaction to sexual stimuli and the quality of sexual responses.

Ovarian androgen production comprises 50% of the total testosterone level in women. This level drops dramatically after oophorectomy, diminishing the neurobiological aspects of the sexual response. Decreased muscle strength and fatigue have also been linked with decreased androgen levels, further hindering libido.13 The ovary continues secreting androgens after menopause. Therefore, after naturally induced menopause, women experience only a slight, gradual decline in androgen levels and typically experience fewer sexual problems than women who have had oophorectomy.

Decreased estrogen levels can influence a woman’s sexual function as well. Delayed clitoral reaction, decreased vaginal lubrication, diminished circulatory response during sexual stimulation, and reduced contractions during orgasm have all been linked to decreases in circulating estrogen.14 These symptoms can be reversed with hormone replacement therapy, further supporting estrogen’s influence on sexual function.

Motivational Causes

Many factors motivate a woman to engage in sexual activity. Androgen status or biological shifts may be less important than psychosocial factors and health status.15 Stress and poor physical health have been identified as predictors of sexual dysfunction. Some experts suggest that a woman’s sexual desire may originate in her response to her partner’s interest rather than from a spontaneous sexual reaction.16 For women, sexuality extends far beyond hormones and neurotransmitters.2 Research confirms that arousal is often influenced more by thoughts and emotions than by genital feedback.

Motivational, affective and cognitive alterations can be rooted in depression, anxiety, stress or relational conflicts that interfere with nervous system pathways involved in arousal.

Alcohol or drug dependence, outside relationships, personal distress, partner abuse or poor coping skills can influence feelings of sexual desire.16,17 In addition, treatments and procedures such as chemotherapy or mastectomy can influence self-image and interest in sexual contact.

Many patients report complex cognitive and motivational issues that need to be addressed before a healthy sex drive can be achieved. Assessment of these factors is critical to planning treatment and setting reasonable, attainable goals.


About Author

Comments are closed.